FGF21 and metabolic dysfunction-associated steatotic liver disease: Additionally, FGF-21 has been proposed as a non-invasive biomarker for distinguishing MASLD from healthy controls, with levels correlating with liver stiffness.16 These findings underscore FGF-21’s potential as a valuable marker for assessing disease severity, particularly in obesity-driven MASLD.